Malignant
Hyperthermia: Clinical diagnosis and management
Malignant
hyperthermia (MH) is one type of severe reaction and potentially deadly hyper
metabolic crisis that occurs as a complication of general anesthesia. Malignant
hyperthermia is one type of disorder that can be considered a gene-environment
interaction.
Signs and symptoms: The signs, which may arise at
any time during anesthesia, resulting from hyper metabolism in skeletal muscle.
Symptoms of malignant hyperthermia include muscle rigidity, inappropriate
tachycardia, high fever, and fast heart rate. Complications can include
rhabdomyolysis and high blood potassium.
Most
of the malignant hyperthermia individuals have few or no symptoms unless they
are exposed to a triggering agent. The volatile anesthetic gases, such as
halothane, sevoflurane, desflurane, isoflurane, enflurane are the most common triggering agents or the
depolarizing muscle relaxants suxamethonium and decamethonium are used primarily in general anesthesia.
Malignant
hyperthermia-susceptible (MHS) individuals have genetic skeletal muscle
receptor abnormalities, allowing uncontrolled intracellular release of calcium
from the sarcoplasmic reticulum. Prevention of Malignant hyperthermia (MH) involves
avoidance of the triggering anaesthetic agents in patients with a personal or
family history of MH.
Treatment: For Malignant hyperthermia early
recognition and prompt treatment are essential for the patient's survival. In
susceptible individuals, the medications induce the release of stored calcium
ions within muscle cells. That leads to increase in calcium concentrations
within the cells cause the muscle fibers to contract which can help to generate
excessive heat and results in metabolic acidosis. The Malignant hyperthermia diagnosis is based
on symptoms in the appropriate situation. Family members may be tested to see
if they are susceptible by muscle biopsy or genetic testing.
Treatment
must be initiated emergently, as soon as the diagnosis of malignant
hyperthermia (MH) is considered reasonable. Immediate treatment includes discontinuation
of all trigger agents, Antiarrhythmic drug treatment, to maintain high urinary output
most preferred treatments are diuretic and fluid therapy.
Comments
Post a Comment